 SOMERSET, N.J.--BUSINESS WIRE--Legend Biotech Corporation NASDAQ: LEGN Legend Biotech, a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced the latest data results from the combined Phase 1b2 CARTITUDE-1 study NCT03548207 of ciltacabtagene autoleucel cilta-cel, an investigational B-cell maturation antigen BCMA directed chimeric antigen receptor T cell CAR-T therapy, 